【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Hepatitis C Therapies
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Hepatitis C Therapies
2.1 A Brief History of Hepatitis C and Treatments
2.1.1 Genotypes
2.1.2 Symptoms: Acute and Chronic Hepatitis C
2.1.3 Diagnosing Hepatitis C: The Asymptomatic Nature
2.1.4 Risk Factors for Hepatitis C
2.2 Incidence and Prevalence Patterns
2.3 Hepatitis C: Treatment and Prevention
2.3.1 Antivirals: Inhibiting Virus Replication
2.3.1.1 Protease Inhibitors
2.3.1.2 Polymerase Inhibitors
2.3.1.3 NS5A Replication Complex Inhibitors
2.3.2 Interferons: Dual Mode of Action
2.3.2.1 Combination Therapy: Treatment with Interferons and Antivirals
2.3.2.2 Interferon-Free Regimens
2.3.3 Hepatitis C and the Need for a Vaccine
3. The World Hepatitis C Therapies Market, 2015-2025
3.1 Hepatitis C Therapies Market, 2013 and 2014
3.2 The Hepatitis C Therapies Market: Revenue Forecast, 2014-2025
3.2.1 Rising Awareness and Screening: Expanding Treatment Population
3.2.2 Generic Competition in the Hepatitis C Therapies Market
3.2.3 Biosimilar Interferons
3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
3.3 Oral Antivirals Submarket
3.3.1 Oral Antivirals Submarket: Revenue Forecast, 2014-2025
3.3.2 A Strong Developmental Pipeline to Drive Market Growth
3.3.3 All-Oral Treatments for Hepatitis C: Improving Tolerability
3.4 Interferons Submarket
3.4.1 Standard of Care for Hepatitis C
3.4.2 Drawbacks to Interferon Therapy
3.4.3 Declining Revenues 2008-2013
3.4.4 Interferons Submarket: Revenue Forecast, 2014-2025
3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
3.5 Hepatitis C Vaccines Submarket
3.6 Hepatitis C Therapies: Submarket Shares 2013, 2019 and 2025
4. Leading National Hepatitis C Markets, 2015-2025
4.1 Global Prevalence of Hepatitis C, 2013
4.1.1 The Importance of Asia
4.2 Hepatitis C Therapies Market: Regional Breakdown, 2013
4.3 Hepatitis C Therapies Market: Regional Forecast, 2014-2025
4.4 The US
4.4.1 Population Movement and Hepatitis C
4.4.2 The Affordable Care Act and Hepatitis C
4.4.3 Increased Screening towards Target Population
4.4.4 The US Revenue Forecast, 2014-2025
4.5 Leading EU Markets for Hepatitis C Therapies
4.5.1 Regional Prevalence
4.5.2 EU5 Market, 2013
4.5.3 EU5: Revenue Forecasts, 2014-2025
4.5.4 Italy: Revenue Forecast, 2014-2025
4.5.5 Spain: Revenue Forecast, 2014-2025
4.5.6 Germany: Revenue Forecast, 2014-2025
4.5.7 UK: Revenue Forecast, 2014-2025
4.5.8 France: Revenue Forecast, 2014-2025
4.6 Hepatitis C in Asia
4.7 China
4.7.1 Decline in Incidence of Hepatitis C
4.7.2 Rising Middle Class
4.7.3 Hepatitis C Outbreaks
4.7.4 Domestic Drug and Vaccine Development
4.7.5 China: Revenue Forecast, 2014-2025
4.8 Japan
4.8.1 Hepatitis C in Japan
4.8.2 Japan: Revenue Forecast, 2014-2025
4.9 India
4.9.1 Low Awareness Rates
4.9.2 India: Revenue Forecast, 2014-2025
4.10 Russia
4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
4.10.2 Adverse Impact of Western Sanctions on Russian Pharma Market
4.10.3 Russia: Revenue Forecast, 2014-2025
4.11 Brazil
4.11.1Current Disease Prevalence
4.11.2 Brazil: Revenue Forecast, 2014-2025
5. Leading Hepatitis C Therapies, Market Prospects to 2025
5.1 Leading Hepatitis C Therapies, 2014-2025
5.2 Sovaldi (Gilead Sciences)
5.2.1 Recent Revenue Analysis
5.2.2 Gilead Licenses Generic Substitute for Sovaldi for Developing Countries
5.2.3 Sovaldi Revenue Forecast, 2014-2025
5.3 Olysio (Janssen/Medivir)
5.3.1 Recent Revenue Analysis
5.3.2 Combination Regimen of Sovaldi and Olysio
5.3.3 Olysio Revenue Forecast, 2014-2025
5.4 Pegasys (Roche)
5.4.1 Recent Revenue Analysis
5.4.2 Label Expansions and Lifecycle Management Strategies
5.4.3 Pegasys Revenue Forecast, 2014-2025
5.5 Incivek (Vertex/Janssen (J&J)/Mitsubishi Tanabe)
5.5.1 Recent Revenue Analysis
5.5.2 Targeting HCV/HIV Co-Infected Patients
5.5.3 Pipeline Competition May Affect Revenues
5.5.4 Incivek Revenue Forecast, 2014-2025
5.6 PegIntron (Merck & Co.)
5.6.1 Recent Revenue Analysis
5.6.2 Competition from Interferon Biosimilars
5.6.3 Enhancing Drug Life Cycle
5.6.4 PegIntron Revenue Forecast, 2014-2025
5.7 Victrelis (Merck & Co.)
5.7.1 Recent Revenue Analysis
5.7.2 Roche Collaboration
5.7.3 Product Differentiation
5.7.4 Victrelis Revenue Forecast, 2014-2025
5.8 Harvoni (Gilead Sciences)
5.8.1 Gilead-AbbVie Dispute over Ledipasvir/Sofosbuvir Patents
5.8.2Harvoni Revenue Forecast, 2014-2025
5.9 Daklinza (Bristol-Myers Squibb)
5.9.1 Daklinza Revenue Forecast, 2014-2025
5.10 Sunvepra (Bristol-Myers Squibb)
5.10.1 Sunvepra: Synergistic Effect with Daklinza
5.10.2 Sunvepra Revenue Forecast, 2014-2025
6. Hepatitis C Therapies Market: Leading R&D Pipeline Candidates, 2014
6.1 Introduction to Hepatitis C Therapy Candidates
6.2 Protease Inhibitors Pipeline
6.2.1 Vaniprevir (Merck & Co.): Patent Security through 2027
6.2.2 MK-5172 and MK-8742 (Merck & Co.): Phase III
6.2.3 Paritaprevir (formerly ABT-450) (AbbVie): Fast-Tracked into Phase III
6.2.4 Sovaprevir (Achillion Pharmaceuticals): Playing Catch Up
6.2.5 ACH-2684 (Achillion Pharmaceuticals)
6.2.6 Danoprevir (Roche): Testing Out Combination Regimens
6.2.7 Lomibuvir (Vertex Pharmaceuticals)
6.2.8 ABT-493 (AbbVie)
6.2.9 Vedroprevir (Gilead Sciences)
6.2.10 GS-9857 (Gilead Sciences)
6.3 Polymerase Inhibitors Pipeline
6.3.1 ACH-2928 (Achillion Pharmaceuticals)
6.3.2 BMS-791325 (Bristol-Myers Squibb): Phase II
6.3.3 TMC-647055 (Janssen): Phase II
6.3.4 Mercitabine (Roche/Pharmasset): Broad Spectrum Treatment
6.3.5 Setrobuvir (Roche): Non-Nucleoside Inhibitor
6.3.6 VX-135 (Vertex Pharmaceuticals): Interferon- and Ribavirin-Free Regimens
6.3.7 GS-9669 (Gilead Sciences)
6.3.8 PPI-383 (Presidio Pharmaceuticals)
6.4 NS5A Inhibitors Pipeline
6.4.1 ABT-530 (AbbVie)
6.4.2 Samatisvir (Merck & Co.): Acquired from Idenix
6.4.3 GS-5816 (Gilead Sciences)
6.4.4 PPI-668 (Presidio Pharmaceuticals)
6.5 Interferon Pipeline
6.5.1 Locteron (Biolex): Controlled Release Formulation
6.5.2 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effects Profile
6.6 Novel Inhibitors
6.6.1 SCY-635 (SCYNEXIS)
6.6.2 Miraversen (Santaris)
6.6.3 GS-9620 (Gilead Sciences)
6.6.4 RG-101 (Regulus Therapeutics)
6.7 Hepatitis C Pipeline Candidates on Hold or Discontinued, 2014
6.7.1 Alisporivir (Novartis/Debiopharm): Advanced Cyclophin Inhibitor
6.7.2 INX-189 (Bristol-Myers Squibb): Cardiovascular Effects May Halt Development
6.7.3 Idenix Developments Terminated: IDX-189 and IDX-19368
6.7.4 Deleobuvir (Boehringer Ingelheim): Development Discontinued
6.7.5 Faldaprevir (Boehringer Ingelheim): Exiting the Hepatitis C Market
6.8 Leading Hepatitis C Vaccine Pipeline Candidates, 2014
6.8.1 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
6.8.2 GI-5005 (GlobeImmune): Yeast-Based Hepatitis C Vaccine
6.8.3 INO-8000 HCV (Inovio Pharmaceuticals): Therapeutic Vaccine in Phase I Trials
6.8.4 Okairos Inc.: Prophylactic and Therapeutic Vaccine Candidates
7. Leading Companies in the Hepatitis C Therapies Market
7.1 Leading Market Players, 2013 and 2014
7.2 Gilead Sciences
7.2.1 Product Overview and Performance. 2013 and 2014
7.2.2 Recent Developments: Gilead Sciences Acquires Pharmasset
7.2.3 Hepatitis Pipeline: Strong and Diverse
7.2.4 Future Outlook: Strongest Pipeline than Any Other Company
7.3 Johnson & Johnson (Janssen Pharmaceuticals)
7.3.1 Product Overview and Performance, 2013 and 2014
7.3.2 Recent Developments: Acquisition of Alios BioPharma
7.3.3 Hepatitis Pipeline
7.3.4 Future Outlook: Combination Regimens with Olysio
7.4 Roche
7.4.1 Product Overview and Performance. 2013 and 2014
7.4.2 Recent Developments: Partnership with Anadys
7.4.3 Hepatitis Pipeline
7.4.4 Future Outlook: Slowing Demand May Affect Market Dominance
7.5 Bristol-Myers Squibb
7.5.1 Product Overview and Performance. 2013 and 2014
7.5.2 Recent Developments: Strengthening Product Pipeline through Acquisitions
7.5.2.1 Bristol-Myers Squibb Acquires Inhibitex
7.5.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
7.5.4 Future Outlook: Market Set For Intense Competition
7.6 Merck & Co.
7.6.1 Product Overview and Performance. 2013 and 2014
7.6.2 Recent Developments: Merck & Co. Acquires Idenix
7.6.3 Hepatitis Pipeline
7.6.4 Future Outlook: Company Pins Hopes on Launch of Pipeline Therapies
7.7 Leading Hepatitis C Pipeline Companies, 2014
7.7.1 Gilead Sciences
7.7.2 Merck & Co.
7.7.3 AbbVie (Formerly Abbott Laboratories): New Venture into Hepatitis C
7.7.4 Achillion Pharmaceuticals: Next Target for Acquisition
7.7.4.1 Achillion and Gilead
8. Hepatitis C Therapies Market: Industry Trends, 2015-2025
8.1 Strengths and Weaknesses in the Hepatitis C Therapies Market, 2014-2025
8.1.1 Interferon Therapy Has Drawbacks
8.1.2 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
8.2 Opportunities and Threats in the Hepatitis C Therapies Market, 2014-2025
8.2.1 Hepatitis Screening and Diagnosis
8.2.2 Raising Awareness and Overcoming Social Stigma
8.2.3 Personalised Therapy
8.2.4 HIV Co-Infection
8.2.5 Asia
8.3 STEP Analysis of The World Hepatitis C Therapies Market, 2014-2025
8.3.1 Social Development
8.3.1.1 Social Implications in China
8.3.2 Technological Advances
8.3.3 Economic Pressures
8.3.4 Political Issues
8.4 Hepatitis C Vaccines
8.5 Oral Direct-Acting Antivirals
8.5.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
8.5.2 Combining Protease and Polymerase Inhibitors
8.5.3 The Need for Ribavirin
8.5.4 Twelve-Week Treatment Target
8.6 Pharmaceutical Investment in Hepatitis C
8.6.1 Licensing and Partnering Deals
8.6.2 Acquisitions in Hepatitis C
8.6.3 Other Companies of Note for Hepatitis Treatment Developments
9. Research Interviews
9.1 Expert Interview 1: Authority from a Company in the Industry (Views Provided Anonymously)
9.1.1 The Hepatitis C Therapies Market Landscape
9.1.2 Interferon Therapies
9.1.3 The Future Hepatitis C Therapies Market
9.2 Interview with Susan Simon, President of the Hepatitis C Association
9.2.1 Barriers to Treatment
9.2.2 Changes to Treatment in the Past Decade and Coming Years
9.2.3 Support and Awareness for Hepatitis C
10. Conclusions
10.1 State of The Hepatitis Therapies Market, 2013 and 2014
10.2 Growth in The Hepatitis Therapies Market, 2014-2025
10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
10.2.2 Asia as a Hepatitis C Therapies Market
10.3 Concluding Remarks
【レポート販売概要】
■ タイトル：C型肝炎(Hepatitis C)治療薬の世界市場■ 英文：Hepatitis C Therapies: World Industry, R&D And Market Forecasts 2015-2025
■ 発行日：2014年12月
■ 調査会社：visiongain
■ 商品コード：VGAIN4121902
■ 調査対象地域：グローバル
- オンライン宝石販売の世界市場2017-2021ABSTRACTAbout Online Jewelry Retail Jewelry items include necklaces, brooches, rings, bracelets, and earrings. These may be attached to the body or clothes. The term "jewelry" is restricted to durable ornaments, excluding flowers. A key growth factor over the forecast period will be the compatibility of consumers with social and digital platforms. In addition, services such as free shipping and pr …
- BFSI（金融）におけるブロックチェーンの世界市場：コンポーネント別、用途別、組織規模別、業種別Blockchain in BFSI is also called as FinTech blockchain. Wide dissemination of blockchain by financial organizations from the past years has witnessed rise in popularity of cryptocurrencies, and the initial coin offering (ICO). As well as blockchain is panacea for all fintech companies’ digital concerns such as security. Blockchain as a technology was developed to serve as the public transaction l …
- 堅牢型ノートパソコンの世界市場2015-2019About rugged notebook The only difference between a rugged notebook and a standard notebook is the toughness. A rugged notebook is designed in such a way that it can withstand harsh environmental factors such as dust, rain, cold, and high temperature. To classify a notebook is rugged or not, it has to undergo a series of tests. Rugged notebooks are mainly designed for sectors such as military, law …
- Indian Pharmaceutical Market Outlook – Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investmentIndian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment Summary GBI Research’s new report “Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment” provides in-depth analysis of the trends, issues …
- 2014年戦略提言：アメリカのPT&APTTポイントオブケア（POC）検査市場This new 337-page report from Venture Planning Group contains 31 tables, and provides a comprehensive analysis of the PT and APTT testing in POC locations, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effec …
- PETパッケージングの世界市場：非結晶性PET、結晶性PET、ボトル・瓶、バック・ポーチ、トレー、蓋/キャップ・クロージャMarketsandMarkets projects that the PET packaging market will grow from USD 57.64 Billion in 2016 to USD 74.32 Billion by 2021, at an estimated CAGR of 5.21%. The market for PET packaging is growing due to growth in end-use industries such as food, beverage, personal care, and pharmaceutical, and rise in demand of sustainable & recyclable packaging. The emerging economies such as India, South Afri …
- 炭素繊維プリプレグの世界市場The global carbon fiber prepreg market was valued at $2,633.0 million in 2014 and is estimated to reach $4,640.2 million by 2019, at a CAGR of 11.9% during the period under consideration. In this report, the global carbon fiber prepreg market has been broadly classified on the basis of application and geography. The application segment is divided into aerospace & defense, wind, sporting goods, and …
- 風力発電産業向けナセル搭載LIDARシステムの世界市場2017-2021About Nacelle Mounted LIDAR Systems Market for Wind IndustryNacelle LIDAR is used to measure the wind speed and the direction of the wind directly ahead of the turbine. Although it is installed on the nacelle, it can measure the wind without being affected by the turbine. The main purpose of the installing nacelle LIDAR is for integration for turbine control and as a retrofit for independently mea …
- スマートグリッドT&D（送電・配電）装置の世界市場2016-2020About Smart Grid Transmission and Distribution Equipment Globally the power T&D network is undergoing a transformation with the introduction of digital technologies into the grid; it is largely driven by the need for efficiency, improved reliability and the integration of diverse power generation sources. The traditional grid was designed to manage continuous power from sources such as coal, oil, …
- 変更・構成管理ソフトウェアの世界市場2015-2019About Change and Configuration Management Change and configuration management are the keys to product development. The process of generating market and customer demands and innovative ideas, and integrating and turning them into feasible products cannot be realized without managing the changes in product development. The changes are acceptable in the early stages of development and design cycle; h …
- 世界の渦流量計市場2015The Global Vortex Flowmeter Industry Report 2015 is a professional and in-depth study on the current state of the Vortex Flowmeter industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Vortex Flowmeter market analysis is provided for the international markets including development trends, competitive lan …
- 保護包装の世界市場2016-2020About Insulated Packaging Insulated packaging offers protection from damage to industrial products, foods and beverages, pharmaceutical products, and equipment during shipping and storage. The global insulated packaging market is influenced by demographic trends, such as growing urbanization, population growth, an increase in international trading activities, and industrialization. The various typ …
- ナイロン6・ナイロン6の世界市場：製品別（ナイロン6、ナイロン66）、用途別（エンジニアリングプラスチック、自動車、繊維、電気・電子、その他）、セグメント予測The global nylon 6 and 66 market size is expected to reach USD 41.13 billion by 2025, expanding at a CAGR of 6.2% over the forecast period, according to a new study by Grand View Research, Inc. Increasing global automobile production is anticipated to drive the growth. Automobile is a highly concentrated industry. Although the product range is high owing to a large number of market participants, a …
- 世界の光ファイバコネクタ市場2015The Global Fiber Optic Connectors Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Fiber Optic Connectors industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Fiber Optic Connectors market analysis is provided for the international markets including d …
- （クメン）シクロペンタジエニル（II）ヘキサフルオロホスフェートの世界市場2015(Cumene)cyclopentadienyliron(II) Hexafluorophosphate (CAS 32760-80-8) Market Research Report 2015 aims at providing comprehensive data on (Cumene)cyclopentadienyliron(II) Hexafluorophosphate market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes (Cumene)cyclopentadienyliron(II) Hexafluorophosphate description, covers its application areas, manufacturin …
